Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commences

SYDNEY, May 20, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with...